
## Shadan Lalezari

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5320917/publications.pdf Version: 2024-02-01



#	ARTICLE	IF	CITATIONS
1	The potential role of emicizumab prophylaxis in severe von Willebrand disease. Blood Cells, Molecules, and Diseases, 2021, 87, 102530.	1.4	9
2	Women with Hemophilia: Case Series of Reproductive Choices and Review of Literature. TH Open, 2021, 05, e183-e187.	1.4	3
3	Confirmed longâ€ŧerm safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study. Haemophilia, 2021, 27, e347-e356.	2.1	12
4	Safety and efficacy of BAY 94–9027, an extendedâ€halfâ€life factor VIII, during minor surgical procedures in patients with severe haemophilia A. Haemophilia, 2021, 27, e559-e562.	2.1	4
5	Molecular Mechanisms of Skewed X-Chromosome Inactivation in Female Hemophilia Patients—Lessons from Wide Genome Analyses. International Journal of Molecular Sciences, 2021, 22, 9074.	4.1	8
6	BAY 81â€8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for â‰⊉Âyears. European Journal of Haematology, 2020, 104, 594-601.	2.2	3
7	Target joint resolution in patients with haemophilia A receiving longâ€ŧerm prophylaxis with BAY 94à€9027. Haemophilia, 2020, 26, e201-e204.	2.1	5
8	Population pharmacokinetic (PopPK) modelling indicates that patients switching to BAY 81â€8973 from rFVIIIâ€FS can continue their dosing schedule with improved protection. Haemophilia, 2020, 26, e145-e147.	2.1	4
9	Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAYÂ94-9027 for Severe HaemophiliaÂA: A Post Hoc Analysis. Advances in Therapy, 2020, 37, 2763-2776.	2.9	1
10	The Potential Role of Emicizuamb Prophylaxis in Severe Von Willebrand Disease. Blood, 2020, 136, 20-20.	1.4	0
11	BAY 94â€9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results. Haemophilia, 2019, 25, 1011-1019.	2.1	23
12	Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial. Thrombosis Research, 2019, 183, 13-19.	1.7	21
13	Neonatal circumcision in patients with haemophilia is safe – a single centre experience. The Journal of Haemophilia Practice, 2017, 4, 32-34.	0.4	0
14	Acquired Hemophilia A in a Patient with Non-Small Cell Lung Carcinoma: A Rare Paraneoplastic Phenomenon. Israel Medical Association Journal, 2017, 19, 128-130.	0.1	2
15	Rationale for Investigator-Assigned Prophylaxis Dosing Frequency in the Leopold I Study. Blood, 2016, 128, 4984-4984.	1.4	1
16	Efficacy, PK and Safety Results of a Phase I/II Clinical Trial of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Haemophilia B (PROLONG - 9FP). Blood, 2012, 120, 1121-1121.	1.4	1
17	Methylenetetrahydrofolate Reductase Genotypes and Early-Onset Coronary Artery Disease. Circulation, 1999, 100, 2406-2410.	1.6	71